Comparative Pharmacology
Head-to-head clinical analysis: CIS PYRO versus INDIUM IN 111 OXYQUINOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS PYRO versus INDIUM IN 111 OXYQUINOLINE.
CIS-PYRO vs INDIUM IN 111 OXYQUINOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cis-pyro is not a recognized pharmaceutical agent. No mechanisms data available.
Indium In 111 oxyquinoline is a radiolabeled compound that chelates indium-111 with oxyquinoline. The lipophilic complex penetrates cell membranes and binds to intracellular components, primarily in leukocytes (neutrophils). After intravenous injection, the radiolabeled cells accumulate at sites of inflammation or infection, allowing gamma camera imaging to detect focal areas of abnormal leukocyte localization.
Not applicable: CIS-PYRO is a pyrophosphate-based radiopharmaceutical used in cardiac imaging, not a therapeutic drug. Standard adult dose: 555-1110 MBq (15-30 mCi) intravenously once.
1-2 mCi (37-74 MBq) labeled autologous leukocytes, administered intravenously over 1-2 minutes.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (IV); prolonged in renal impairment (up to 30 hours in ESRD).
Terminal elimination half-life is approximately 4-6 hours for the free indium ion, but biological half-life for labeled cells can be 1-2 days depending on cell type.
Primarily renal excretion: 65-80% unchanged in urine; biliary/fecal excretion accounts for 15-25%.
Renal excretion approximately 70-80% within 24 hours; fecal excretion less than 5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical